PATH Malaria Vaccine Initiative

Dr. Emily Locke

The PATH Malaria Vaccine Initiative (MVI) is a global vaccine development program established at PATH in 1999 through an initial grant from the Bill & Melinda Gates Foundation. PATH is an international, nonprofit organization that creates sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH’s work improves global health and well-being. MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world.

As partner in the OPTIMALVAC program, MVI will provide a crucial role in linking European scientists funded under this program with their counterparts in assay harmonization activities located primarily in the United States. To further the efforts that will be undertaken, MVI will support the involvement of the UK National Institute of Biological Standards and Controls (NIBSC) in its central role of coordinating all the assay harmonization proficiency panel exercises. This role involves distributing, aliquoting, and coding reagents, and in some cases, developing standards. MVI’s parallel and linking activities will contribute to the success of this program by fostering global communication and collaboration and reducing duplicity of efforts.

IFA. MVI is supporting several activities focused, in particular, on the sporozoite IFA. The estimated level of MVI’s contribution to this effort is five person months.

ADCI. MVI is supporting the production of the RAM1 anti-MSP3 monoclonal antibody, a positive control for the antibody dependent cellular inhibition (ADCI) assay. The estimated level of MVI’s support toward this effort is five person months.

T cell assays. MVI is funding acquisition of peripheral blood mononuclear cells (PBMCs) that will be distributed to labs participating in the T cell assay proficiency panels. The estimated level of MVI’s support toward this effort is 5 person months.